AstraZeneca Investor Day Presentation Deck
Conclusions
25
●
• A single priming dose of tremelimumab plus regular interval durvalumab with the STRIDE (T300+D) regimen
statistically significantly improved overall survival versus sorafenib
Median overall survival was 16.4 months for STRIDE (T300+D) and 13.8 months for sorafenib
STRIDE (T300+D) appeared to provide a long-term survival benefit, with a landmark 36-month
overall survival of 30.7%
●
The HIMALAYA study was a large, Phase 3 study that included a global, heterogeneous population, representative of
patients with uHCC
●
●
●
Overall survival for durvalumab monotherapy was noninferior to sorafenib, with a favorable benefit-risk profile
Both STRIDE (T300+D) and durvalumab monotherapy had manageable safety profiles, with lower rates of grade 3/4
TRAES and TRAEs leading to discontinuation than sorafenib and no increase in liver toxicity or bleeding risk
The STRIDE (T300+D) regimen and durvalumab monotherapy
may represent new treatment options for patients with uHCCView entire presentation